Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KQ-2003 for Relapsed/Refractory POEMS Syndrome
NCT06518876Phase 1Not yet recruiting
- Sponsor
- Novatim Immune Therapeutics
- Start
- Aug 2024
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of KQ-2003 in POEMS syndrome (POEMS) (4 arms), sponsored by Novatim Immune Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 2 years and 2 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
KQ-2003
03
Conditions
POEMS syndrome (POEMS)
Beyond the preview
Go deeper on NCT06518876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06518876.